Navigation Links
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
Date:10/23/2008

ng those caused by MRSA, as well as community acquired pneumonia. Novexel's future clinical development with NXL103 is expected to focus on its potential to be used in hospitals as an oral agent for the treatment of infections caused by Gram positive organisms, including resistant pathogens such as MRSA. Currently, physicians have a very limited choice of anti-MRSA antibacterials when they wish to switch from intravenous (IV) to oral treatment, a key step prior to a patient being discharged from the hospital.

In the second quarter of 2008 sanofi-aventis elected not to exercise its option to develop and commercialise NXL103. Consequently, worldwide rights to the NXL103 programme are retained by Novexel.

Iain Buchanan, Novexel's CEO, commenting on the announcement said, "We are very pleased that the results from our first Phase II clinical trial with NXL103 are positive. The data from this trial confirm the efficacy of NXL103 in patients with mild to moderate CAP. Furthermore, the pre-clinical and clinical work that we have carried out to-date with NXL103 provides a compelling platform for Phase III development. We believe that with its potent activity against MRSA, NXL103 may offer physicians an important therapeutic option when they switch patients from IV to oral treatment prior to discharge from the hospital."

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel anti-bacterials designed to overcome the significant global problem of bacterial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the in
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
5. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
6. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
7. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
8. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
9. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015 IRIDEX ... will release its second quarter 2015 financial results after ...   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/30/2015)...  Unichem Pharmaceuticals ( USA ), Inc. ... 25 mg 1000-count bottle to the consumer level. This ... to the identification of a Clopidogrel tablet found in ... risk associated with mistakenly taking a Clopidogrel tablet instead ... experiencing Clopidogrel,s side effects which include bleeding and/or bruising. ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... SADDLE BROOK, N.J., Jan. 6, 2011 The FDA,s nod ... options they have to address the problems of sexual dysfunction. ... president of Semprae Laboratories, Inc. The announcement of the approval ... of Flibanserin. Dubbed the "pink pill," the female Viagra equivalent, ...
... COVINGTON, Ky., Jan. 6, 2011 Bexion Pharmaceuticals, LLC announced today ... Board of Directors. Dr. Crawford has had a ... academia. Over ten years of his career were spent at the ... roles and culminating in his appointment as FDA Commissioner. ...
Cached Medicine Technology:What About Us? The State of Women's Sexual Health in Question 2Former FDA Commissioner Joins Bexion Pharmaceuticals Board 2
(Date:8/1/2015)... IN (PRWEB) , ... August 02, 2015 , ... Back ... cause in a school, however, back packs can wreck havoc on a kid's spine. ... carry their supplies to and from school. Make sure you are aware of how ...
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are ... and women often causing pain and discomfort. Those who spend a lot of time ... Northeast Houston Vein Center is doing what it can to create awareness and provide ...
(Date:8/1/2015)... ... 01, 2015 , ... Brig and Lita Hart, icons of the network marketing ... Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been a ... have agreed to join their missions of purpose together to change the course of ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Lume Wellness creators ... is free to download on the Apple AppStore. , The app is designed ... mood, thus acting as a tool to view personal health and use this information ...
(Date:8/1/2015)... ... ... 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) ... Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles in ... friends and family. He visited CCAR and left an inspirational message to his staff: ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... Market Will Be Driven by Launches, of Disease-Modifying Therapies, According ... ... Resources, WALTHAM, Mass., Sept. 24 Decision ... and,healthcare issues, finds that by 2016 Genentech/Roche,s Lucentis and Eli,Lilly,s ruboxistaurin ...
... Project Pink Campaign Supports Susan G. Komen for the Cure with its ... Celebrity eBay Auction this October, WHAT: Emmy Award-winning journalist and TV ... in Munchkin,s Project Pink Campaign. ... products -- is once again reminding women everywhere "Don,t Duck ...
... the best ways to encourage an individual to ... a personalized approach, according to researchers at Jefferson ... that simple, personalized interventions that guide recipients through ... screening rates in primary care practices. , Ronald ...
... methods significantly raise exam rate, study finds , MONDAY, ... doctors, offices can improve colorectal cancer screening rates, a ... most common kind of cancer and the third leading ... patients don,t experience any symptoms until the disease is ...
... proprietary PhreesiaPad The first free ... DIEGO and NEW YORK, Sept. 24 At ... offer a free patient check-in,solution in the physician,s ... the check-in process, Phreesia delivers fully,interactive relevant health ...
... Meadow Farms world,s first commercial adopter of vaccine ... Bioniche Life,Sciences Inc. (TSX: BNC), a research-based, technology-driven ... E. coli,O157:H7 in cattle has been used for ... Meadow Farms, an Ontario-based producer of premium beef,integrated ...
Cached Medicine News:Health News:Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets 2Health News:Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research 2Health News:Jefferson researchers find personalized interventions key to improving colon cancer screening rates 2Health News:Doctors' Office Outreach Boosts Colon Cancer Screening 2Health News:Phreesia Launches at DEMOfall 07 2Health News:Phreesia Launches at DEMOfall 07 3Health News:Beef Cattle Vaccinated Against E. coli O157:H7 2Health News:Beef Cattle Vaccinated Against E. coli O157:H7 3
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
Medicine Products: